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B-cell lymphomas (BCLs) represent the most frequent lymphoid
neoplasms. They include rare precursor lymphoblastic leukemia/
lymphomas, B-cell chronic lymphocytic leukemias, mantle zone
lymphomas, marginal zone lymphomas, follicular lymphomas
and most of the Hodgkin’s lymphomas (Sha¡er et al, 2002). Only
a minority of B-cell lymphomas actually occurs in the skin (Burg
et al, 1997; Dummer et al, 2000). The origin of human BCLs has
been studied extensively using the various approaches of histol-
ogy, immunohistochemistry, karyotyping, single cell analysis
and somatic mutation study of variable-region genes (Sha¡er
et al, 2001; Sha¡er et al, 2002). In order to understand the biology
of BCLs, it is reasonable to classify them according to their pre-
sumed normal counterpart in the B-cell di¡erentiation process.
Despite their origin in human B-cell development, BCLs still re-
main a controversial topic in terms of their precise classi¢cation
and diagnosis. Standard immunohistochemistry and molecular
biology has often failed to identify the malignant ‘‘clonal’’ B-cell
populations. Even in Southern blot-positive cases, the origin or
relationship of a malignant cell to any particular stage in B-cell
development remains unclear. The germinal center cell reaction
is essential for the education of a B lymphocyte since it modi¢es
naive B-cells through somatic hypermutation, class switching and
receptor editing, and is thus critical for an accurate classi¢cation
of BCLs (Kuppers et al, 1999; Sha¡er et al, 2002). Based on the
molecular status of the immunoglobulin gene, a B lymphocyte
can be characterized into a so-called ‘‘pregerminal center’’ B cell
that carries no mutations in the variable-region genes (Kuppers
et al, 1999; Sha¡er et al, 2002). This may be distinguished from a
‘‘postgerminal center’’ B cell that presents somatic mutations in
the variable-region genes on a single cell level (Kuppers et al,
1999; Sha¡er et al, 2002).
Recent studies using gene expression pro¢ling have shown
that lymphomas and leukemias which are histologically di⁄cult
to distinguish can nevertheless be molecularly distinct diseases
(Golub et al, 1999; Alizadeh et al, 2000), providing strong evidence
that tumor expression pro¢les can be used for cancer classi¢ca-
tion. Using genes that de¢ne germinal center B-cell signatures,
Alizadeh et al could show that di¡use large B-cell lymphomas
consist of two distinct groups, carrying either an activated per-
ipheral blood B-cell or a normal germinal center B-cell pheno-
type (Alizadeh et al, 2000). Most interesting is the fact that the
group with an activated B-cell signature had signi¢cantly poorer
survival compared with the center type (Alizadeh et al, 2000).
This and the work of Shipp et al (2002) demonstrates that in ad-
dition to resolving classi¢cation problems, expression pro¢ling
can add value to existing clinical prognostic parameters.
Primary cutaneous B-cell lymphomas (CBCLs) are rare
diseases (Dummer et al, 2000). They account for approximately
25% of all cutaneous lymphomas (estimated annual incidence
0.2/100,000/year) (Burg et al, 1997). Even for true ‘‘lymphoma-
niacs,’’ a convincing classi¢cation for primary cutaneous B-cell
lymphomas is still far from being de¢ned. The European Orga-
nization for Research and Treatment of Cancer (EORTC) classi-
¢cation distinguishes between indolent CBCLs (follicle center
cell lymphoma, immunocytoma, marginal zone B-cell lympho-
ma), CBCLs with intermediate clinical behavior (large B-cell
lymphoma of the leg), and the provisional entities (intravascular
large B-cell lymphoma and plasmocytoma) (Santucci et al, 1991;
Willemze et al, 1997). This classi¢cation scheme is still under
debate.
In this issue of the Journal of Investigative Dermatology, there is an
interesting article from Storz et al giving us for the ¢rst time the
opportunity to look into gene expression pro¢les of primary
CBCLs (Storz et al, 2003). Using the unsupervised, hierarchical
clustering method the authors explore the relationship among
lymphoma, normal skin and tonsil samples, trying to identify
the molecular signatures in lymphoma specimens that might re-
late to their normal counterparts in skin and tonsil. Clustering
analysis reveals that the follicular center cell lymphoma (FCCL)
samples group more or less together, implying that these tumors
share a similar overall gene expression pattern. It is of note that
two of the FCCL samples from the same patient taken two years
apart did not cluster next to each other, although they remained
in the same branch. Follow-up studies will elucidate whether this
phenomenon is due to the changes of the malignant clone over
time or to the sensitivity of the array technique itself.
Di¡use large cell lymphoma (DLCL) and marginal zone lym-
phoma (MZL) samples fail to demonstrate a speci¢c clustering
pattern. Primary DLCL, however, cluster adjacent to FCCL sam-
ples, whereas secondary DLCL cases are removed from these two
groups, suggesting a biological and molecular distinctiveness.
Subsequently, the authors focus on gene clusters associated with
T- and B-cell lineages and development, delineating T-cell, B-
cell germinal center (GC) and plasma cell ‘‘signatures,’’ respec-
tively. Storz et al detected characteristic B-cell GC signature in
tonsil, primary and secondary FCCL, and in primary DLCL,
suggesting that these diseases are more closely related than ex-
pected from recent histological and immunohistological analyses.
This may indeed be the case in some clinical situations where
DLCL of the skin react similarly to FCCL. We have recently
described a large cell lymphoma responsive to antibiotic treat-
ment (Hofbauer et al, 2001), as are some primary cutaneous FCCL
(Cerroni et al, 1997; Hofbauer et al, 2001).
Interestingly, secondary DLCL lacked the expression of B-cell
GC signature. Plasma cell signature on the other side could be
identi¢ed in two out of ¢ve MZL with prominent plasmacytoid
di¡erentiation.
Although the study only comprises a small number of cases,
Storz et al provide the ¢rst insight into the molecular pro¢les of
most common subtypes of CBCL. As with nodal lymphomas,
there is hope that with the help of high-throughput microarray
technology, we will be able to characterize the nature of di¡erent
primary cutaneous lymphoma entities and subsequently improve
existing lymphoma classi¢cations.
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